1,128 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
hlx208 Non-Small Cell Lung Carcinoma	Shanghai Henlius Biotech	P2	CCC (54)
hs-10365 Non-Small Cell Lung Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P2	CCC (54)
hs-20093 Non-Small Cell Lung Carcinoma	Hansoh BioMedical R&D Company	P3	CCC (54)
Hydroxychloroquine Non-Small Cell Lung Carcinoma	Abramson Cancer Center at Penn Medicine	P2	CCC (54)
ibi351 Non-Small Cell Lung Carcinoma	Guangdong Association of Clinical Trials	P2	CCC (54)
Immunoglobulin G4 [221-Proline], Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Sg001 ?4-Chain), Disulfide With Human Monoclonal Sg001 ?-Chain, Dimer Non-Small Cell Lung Carcinoma	CSPC Megalith Biopharmaceutical Co.,Ltd.	P3	CCC (54)
Iodized Ethyl Esters Of Poppyseed Fatty Acids Non-Small Cell Lung Carcinoma	City of Hope Medical Center	P2	CCC (54)
Itraconazole Non-Small Cell Lung Carcinoma	Eli Lilly and Company	P2	CCC (54)
Jskn016 Non-Small Cell Lung Carcinoma	Shanghai Pulmonary Hospital, Shanghai, China	P2	CCC (54)
mk-3475 Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P3	CCC (54)
nc318 Non-Small Cell Lung Carcinoma	NextCure, Inc.	P2	CCC (54)
Nogapendekin Alfa Non-Small Cell Lung Carcinoma	SWOG Cancer Research Network	P2/3	CCC (54)
rc148 Non-Small Cell Lung Carcinoma	RemeGen Co., Ltd.	P3	CCC (54)
Recombinant Ephb4-Hsa Fusion Protein Non-Small Cell Lung Carcinoma	University of Southern California	P2	CCC (54)
Regorafenib Non-Small Cell Lung Carcinoma	Neonc Technologies, Inc.	P2	CCC (54)
Sevabertinib Non-Small Cell Lung Carcinoma	Bayer	P3	CCC (54)
Shr-A2009 Non-Small Cell Lung Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P3	CCC (54)
sy-5007 Non-Small Cell Lung Carcinoma	Shouyao Holdings (Beijing) Co. LTD	P3	CCC (54)
Tunlametinib Non-Small Cell Lung Carcinoma	Sun Yat-sen University	P2	CCC (54)
Upifitamab Rilsodotin Non-Small Cell Lung Carcinoma	Mersana Therapeutics	P1/2	CCC (54)
XENON Non-Small Cell Lung Carcinoma	Xemed LLC	P2	CCC (54)
(1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil 1:4 Non-Small Cell Lung Carcinoma	AstraZeneca	P3	CCC (53)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Non-Small Cell Lung Carcinoma	Kura Oncology, Inc.	P2	CCC (53)
Bio 300 Non-Small Cell Lung Carcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Bms-986504 Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P2/3	CCC (53)
Cobimetinib Non-Small Cell Lung Carcinoma	Cancer Research UK	P2/3	CCC (53)
Daraxonrasib Non-Small Cell Lung Carcinoma	Revolution Medicines, Inc.	P1/2	CCC (53)
Disitamab Non-Small Cell Lung Carcinoma	Sun Yat-sen University	P2	CCC (53)
eik1001 Non-Small Cell Lung Carcinoma	Eikon Therapeutics	P2/3	CCC (53)
Erythromycin Non-Small Cell Lung Carcinoma	Qianfoshan Hospital	P3	CCC (53)
Etrumadenant Non-Small Cell Lung Carcinoma	Gilead Sciences	P2	CCC (53)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Met (Met Proto-Oncogene, Hepatocyte Growth Factor (Hgf) Receptor, Hgfr, Scatter Factor (Sf) Receptor, Hgf/Sf Receptor, Receptor Tyrosine-Protein Kinase C-Met, Papillary Renal Cell Carcinoma 2, Rccp2)] And Anti-[Homo Sapiens Egfr (Epidermal Growth Factor Receptor, Receptor Tyrosine-Protein Kinase Erbb-1, Erbb1, Her1, Her-1, Erbb)], Homo Sapiens Monoclonal Antibody, Bispecific Non-Small Cell Lung Carcinoma	Betta Pharmaceuticals Co., Ltd.	P2	CCC (53)
Indocyanine Green Non-Small Cell Lung Carcinoma	St. Joseph's Healthcare Hamilton	P2	CCC (53)
Lurbinectedin Non-Small Cell Lung Carcinoma	Fox Chase Cancer Center	P2	CCC (53)
Naptumomab Estafenatox Non-Small Cell Lung Carcinoma	NeoTX Therapeutics Ltd.	P2	CCC (53)
Ociperlimab Non-Small Cell Lung Carcinoma	Novartis Pharmaceuticals	P3	CCC (53)
Repotrectinib Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P3	CCC (53)
Tocilizumab Non-Small Cell Lung Carcinoma	University of Pennsylvania	P2	CCC (53)
Tucatinib Non-Small Cell Lung Carcinoma	Jonathan Riess	P2	CCC (53)
Uliledlimab Non-Small Cell Lung Carcinoma	TJ Biopharma Co., Ltd.	P2/3	CCC (53)
ak146d1 for Non-Small Cell Lung Carcinoma	Akeso	P2	CCC (52)
Balstilimab Non-Small Cell Lung Carcinoma	Immune Oncology Research Institute	P2	CCC (52)
Botensilimab Non-Small Cell Lung Carcinoma	Immune Oncology Research Institute	P2	CCC (52)
Budigalimab Non-Small Cell Lung Carcinoma	AbbVie	P2/3	CCC (52)
Dalmitamig Non-Small Cell Lung Carcinoma	Regeneron Pharmaceuticals	P2	CCC (52)
Denosumab Non-Small Cell Lung Carcinoma	China Medical University, China	P3	CCC (52)
D-Thioctic Acid Non-Small Cell Lung Carcinoma	Ain Shams University	P2	CCC (52)
Encorafenib Non-Small Cell Lung Carcinoma	Peking University Cancer Hospital & Institute	P2	CCC (52)
ff-10832 Non-Small Cell Lung Carcinoma	Fujifilm Pharmaceuticals U.S.A., Inc.	P2	CCC (52)
Fianlimab Non-Small Cell Lung Carcinoma	Montefiore Medical Center	P2/3	CCC (52)

Showing 251 to 300 of 1,125 assets

PreviousPage 6 of 23Next